Salarius Pharmaceuticals to Present During Virtual LD 500 Conference
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2020 LD 500 Conference, taking place virtually from September 1-4, 2020. Arthur's presentation will cover Salarius' business overview and recent clinical achievements, particularly for its lead compound, seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The presentation is scheduled for September 1 at 3:20 PM ET, with a live webcast available for attendees.
- None.
- None.
HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present during the 2020 LD 500 Conference. The event will take place September 1-4, 2020 via a virtual technology platform.
Mr. Arthur will present an overview of Salarius’ business and highlight its recent corporate and clinical achievements, as well as the anticipated milestones in its clinical program for its lead compound, seclidemstat. Seclidemstat is a reversible LSD1 inhibitor now undergoing two Phase 1/2 clinical trials in Ewing sarcoma, a rare and deadly pediatric bone cancer, and advanced solid tumors (AST). Members of the Salarius management team will be available to participate in one-on-one virtual meetings with investors who are registered to attend the conference.
Details of Salarius’ presentation are as follows:
| Event: | LD 500 Conference |
| Date: | Tuesday, September 1, 2020 |
| Time: | 3:20 PM (ET) |
| Live Webcast: | https://www.webcaster4.com/Webcast/Page/2019/36538 |
The live webcast of the presentation will be available by clicking the registration link or visiting the upcoming events section of the Company’s website at www.salariuspharma.com. The webcast will also be available for replay on the conference website following the event.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will,” "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/Miriam Miller
(212) 375-2664/ 2694
mmcenroe@tiberend.com/mmiller@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Johanna Bennett
(212) 375-2686
jbennett@tiberend.com
FAQ
What is the date of Salarius Pharmaceuticals' presentation at the LD 500 Conference?
What time will David Arthur present at the LD 500 Conference?
What is seclidemstat being tested for in Salarius Pharmaceuticals' clinical trials?
What designations has seclidemstat received from the FDA?
How can I access the live webcast of Salarius Pharmaceuticals' presentation?
